<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Gonorrhoea</h1><p><strong>BASHH 2025 UK National Guideline on <em>Neisseria gonorrhoeae</em></strong> (2025 update)</p><h4 class="text-base font-semibold mt-4 mb-2"><strong>1. Key updates since 2018 (high-yield)</strong></h4><ul><li><strong>Universal pharyngeal sampling</strong> for everyone with urogenital gonorrhoea <strong>&amp; all contacts</strong>. </li><li><strong>Cefixime dose doubled</strong> to 400 mg <strong>twice</strong> (6–12 h apart). </li><li><strong>Ciprofloxacin removed</strong> from first-line list; still usable if susceptibility proven &amp; clinically appropriate. </li><li><strong>Routine TOC</strong> no longer needed for ceftriaxone-susceptible anogenital infection treated with 1 g IM. </li><li>Expanded guidance on <strong>DGI &amp; ocular infection</strong>;. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>2. Epidemiology &amp; Aetiology</strong></h4><ul><li>2nd commonest bacterial STI in UK</li><li>highest rates in GBMSM</li><li>15–24 yr olds</li><li>Black Caribbean ethnicity &amp; deprived areas. </li><li>Caused by <strong>Gram-negative diplococcus</strong> <em>N. gonorrhoeae</em> with marked antimicrobial-resistance (AMR) potential; </li><li>Ceftriaxone resistance remains rare in England/Wales but prevalent in Asia-Pacific. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>3. Clinical spectrum (link to exam viva)</strong></h4><table><tr><td><p><strong>Site</strong></p></td><td><p><strong>Typical features</strong></p></td><td><p><strong>Key pitfalls</strong></p></td><td><p class="mb-3"><strong>Treatment</strong></p></td></tr><tr><td><p>Penile urethra</p></td><td><p>Discharge/dysuria in &gt;90 %; 2–5 d incubation</p></td><td><p>Mycoplasma / Chlamydia co-infection common </p></td><td rowspan="4"><p class="mb-3">Ceftriaxone 1 g IM single dose  Alternative: Cefixime 400 mg PO x2 + Azithro 2 gAlternative: Gentamicin 240 mg IM + Azithro 2 gAlternative: Azithro 2gAlternative: Ciprofloxacin 500mg    </p></td></tr><tr><td><p>Cervix</p></td><td><p>50 % vaginal discharge, ±abdo pain; PID risk 14 %</p></td><td><p>Microscopy insensitive (&lt;50 %)</p></td></tr><tr><td><p>Rectum</p></td><td><p>Usually asymptomatic; consider in women without anal sex history</p></td><td></td></tr><tr><td><p>Pharynx</p></td><td><p>Largely asymptomatic; harder to eradicate</p></td><td></td></tr><tr><td><p>DGI</p></td><td><p>Septic arthritis (&gt;80 %), fever, bacteraemia; negative mucosal tests in 50 %</p></td><td><p>Collect synovial fluid + blood cultures + all mucosal sites </p></td><td><p class="mb-3">Ceftriaxone 1 g IV/IM q24 hStep down: cefixime 800 mg BD7d arthritis; 14d meningitis; 28d endocarditis</p></td></tr><tr><td><p>Ocular</p></td><td><p>Purulent conjunctivitis, rapid keratitis → perforation</p></td><td><p>Urgent systemic + topical Rx</p></td><td><p class="mb-3">Ceftriaxone 1 g IM + cefuroxime 5 % drops hourly; ophthalmology referral.   </p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>4. Laboratory diagnosis (exam-favourite)</strong></h4><p><strong>Microscopy</strong></p><ul><li>Urethral smear (symptomatic males): 90–95 % sens. </li><li>Not recommended for asymptomatic urethra, pharynx; limited in cervix/rectum.</li></ul><p><strong>NAAT</strong> (preferred screening test)</p><ul><li>≥95 % sens across sites; confirm with 2nd target if PPV &lt; 90 % (esp. pharynx). </li><li>Optimal specimens:<ul><li><strong>First-pass urine</strong> (penile urethra).</li><li><strong>Self-/clinician-taken vulvovaginal swab</strong> outperforms endocervical &amp; urine. </li><li><strong>Routine rectal &amp; pharyngeal NAAT</strong> for GBMSM, sex workers &amp; all contacts. </li></ul></li></ul><p><strong>Culture</strong> – essential for susceptibility testing</p><ul><li>Take from every NAAT-positive site <strong>before treatment</strong>. </li><li>Rapid bedside plating or charcoal transport (refrigerate if delay &gt; few h). </li></ul><p><strong>AMR molecular markers</strong></p><ul><li>Commercial assays for <em>gyrA</em> (ciprofloxacin) available; mosaic <em>penA</em> tests pending. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>5. Treatment algorithms</strong></h4><h5><strong>Uncomplicated anogenital ± pharyngeal infection (adults)</strong></h5><table><tr><td><p><strong>Regimen</strong></p></td><td><p><strong>Notes</strong></p></td></tr><tr><td><p><strong>Ceftriaxone 1 g IM single dose</strong></p></td><td><p>Remains first-line; covers ≥99 % UK strains. </p></td></tr><tr><td><p><strong>Cefixime 400 mg PO x2 + Azithro 2 g</strong></p></td><td><p>Only if IM contraindicated <strong>and</strong> susceptibilities known; avoid for pharynx without dual Rx. </p></td></tr><tr><td><p><strong>Gentamicin 240 mg IM + Azithro 2 g</strong></p></td><td><p>Acceptable alt; pharyngeal cure rates lower. </p></td></tr><tr><td><p><strong>Azithro 2 g alone</strong></p></td><td><p>Reserve where absolutely no β-lactam/aminoglycoside possible; high GI SEs &amp; resistance. </p></td></tr><tr><td><p><strong>Ciprofloxacin 500 mg</strong></p></td><td><p>Only if proven susceptible <strong>and</strong> no safer option (MHRA warning). </p></td></tr></table><h5><strong>Complicated disease</strong></h5><ul><li><strong>PID or epididymo-orchitis</strong>: Ceftriaxone 1 g IM <strong>plus</strong> standard PID/EO regimen.</li><li><strong>Ocular</strong>: Ceftriaxone 1 g IM + intensive <strong>cefuroxime 5 % drops hourly</strong>; ophthalmology referral. </li><li><strong>DGI</strong>: Ceftriaxone 1 g IV/IM q24 h; 7 d for arthritis, 10–14 d meningitis, ≥4 wk endocarditis; switch to cefixime 800 mg BD once improved if susceptible. </li></ul><h5><strong>Pregnancy / Breast-feeding</strong></h5><ul><li>Use ceftriaxone; <strong>avoid quinolones &amp; gentamicin</strong>; azithro only if isolate susceptible &amp; alternatives unsuitable. </li></ul><h5><strong>Severe β-lactam allergy</strong></h5><ul><li>Gentamicin + azithro or consult UKHSA for ertapenem guidance if MDR suspected. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>6. Test of Cure (TOC)</strong></h4><table><tr><td><p><strong>Who needs TOC?</strong></p></td><td><p><strong>Timing &amp; method</strong></p></td></tr><tr><td><p>Persistent symptoms, <strong>pharyngeal infection</strong>, unknown susceptibility, non-ceftriaxone regimen, pregnancy</p></td><td><p><strong>NAAT ≥14 days</strong> post-treatment (RNA tests OK ≥7 d for ano-genital, ≥12 d for pharynx) or culture ≥72 h if symptomatic. </p></td></tr><tr><td><p>Anogenital infection treated with ceftriaxone 1 g <strong>and </strong>proven susceptible</p></td><td><p><strong>No routine TOC</strong>.</p></td></tr></table><h4 class="text-base font-semibold mt-4 mb-2"><strong>7. Management of ceftriaxone treatment failure</strong></h4><ul><li>Define as positive culture ≥72 h post Rx or NAAT at 2–3 weeks in absence of reinfection, with MIC &gt; 0.125 mg/L. </li><li>Notify UKHSA/PH Wales/Scotland; send isolates to reference lab.</li><li>Consider <strong>ertapenem 1 g IV daily × 3 d</strong> (case-series evidence) if MIC favourable; consult GRASP team. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>8. Partner management</strong></h4><ul><li><strong>Look-back:</strong><ul><li>Symptomatic urethral males – partners from onset back to <strong>2 weeks</strong> (or last partner if longer).</li><li>All others – <strong>3 months</strong>. </li></ul></li><li><strong>Epidemiological treatment</strong> only if exposure &lt;14 d and high-risk (pregnancy, remote access, psychosocial barriers); otherwise test &amp; await result. </li><li>Doxy-PEP <strong>does NOT cover gonorrhoea</strong> (high tetracycline resistance) – manage as above. </li></ul><h4 class="text-base font-semibold mt-4 mb-2"><strong>9. Auditable standards (good QA stations)</strong></h4><ol><li>Culture for AST <strong>before treatment</strong> – target ≥97 %.</li><li>Appropriate TOC offered where indicated – ≥97 %.</li><li>Concurrent HIV, syphilis, chlamydia tests – ≥97 %.</li><li>Partner notification documented – ≥97 %.</li><li>First-line therapy or documented rationale – ≥97 %.</li><li>Probable/confirmed ceftriaxone failures reported to UKHSA – ≥97 %. </li></ol><h4 class="text-base font-semibold mt-4 mb-2"><strong>10. Hot points for viva/OSPE</strong></h4><ul><li>Explain why <strong>culture is mandatory even when NAAT positive</strong> (AMR surveillance; phenotype confirmation).</li><li>Discuss <strong>NAAT confirmatory algorithms</strong> when PPV low.</li><li>Justify cefixime BID dosing pharmacodynamics (T&gt;MIC).</li><li>Outline MHRA fluoroquinolone safety alert rationale.</li><li>Describe lab &amp; clinical steps when faced with suspected MDR (<em>penA</em> mosaic) isolate.</li></ul><p><strong>Mnemonic for first-line management</strong> – <strong>“1-GONe”</strong></p><p> <em>1 g Ceftriaxone, Gonorrhoea, Oro-pharyngeal sampling, Notify partners &amp; labs, early abstinence (7 days).</em></p>
</div>